Dechra Pharmaceuticals plc (DPH) Receives GBX 1,784 Consensus Price Target from Analysts
Shares of Dechra Pharmaceuticals plc (LON:DPH) have earned an average recommendation of “Buy” from the eight research firms that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is GBX 1,784 ($24.01).
Separately, Jefferies Group boosted their price objective on Dechra Pharmaceuticals from GBX 1,565 ($21.06) to GBX 1,868 ($25.14) and gave the stock a “hold” rating in a research note on Tuesday, September 5th.
Dechra Pharmaceuticals (LON DPH) traded up GBX 15.09 ($0.20) during trading hours on Thursday, reaching GBX 2,055 ($27.66). The company’s stock had a trading volume of 108,977 shares, compared to its average volume of 134,639. Dechra Pharmaceuticals has a 52 week low of GBX 1,225 ($16.49) and a 52 week high of GBX 2,272 ($30.58).
In other Dechra Pharmaceuticals news, insider Ian Page sold 54,910 shares of the business’s stock in a transaction that occurred on Tuesday, September 19th. The stock was sold at an average price of GBX 2,024 ($27.24), for a total transaction of £1,111,378.40 ($1,495,798.65).
About Dechra Pharmaceuticals
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.
Receive News & Ratings for Dechra Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals plc and related companies with MarketBeat.com's FREE daily email newsletter.